Quantum Chemical Investigations on the Hydrolysis of Gold(III)-Based Anticancer Drugs and Their Interaction with Amino Acid Residues

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2021 Nov 1

PMID 34723008

Citations 1

Authors

Amit Kumar Pradhan

Abhijit Shyam

Paritosh Mondal

Affiliations

Soon will be listed here.

Abstract

A comprehensive hydrolysis mechanism of the promising class of Au(III) anticancer drugs [Au(DMDT)Cl] (DMDT = ,-dimethyldithiocarbamate) () and [Au(damp)Cl] (damp = 2-[(dimethylamino)methyl]phenyl) (') was done by means of density functional theory (DFT) in combination with the CPCM solvation model to explore the solution behavior and stability under physiological conditions. The activation free energies (Δ) for the second hydrolysis, (13.7 kcal/mol) and ' (10.0 kcal/mol) are found to be relatively lower in comparison to the first hydrolysis, and their rate constant values are computed to be 5.62 × 10 and 2.90 × 10 s, respectively. Besides these, the interaction mechanisms of aquated and ' with the potential protein-binding sites cysteine (Cys) and selenocysteine (Sec) were also investigated in detail. The kinetic study and activation Gibbs free energy profiles reveal that the aquated complexes of and ' bind more effectively to the Se site of Sec than to the S site of Cys. Intra- and intermolecular hydrogen bonding play a pivotal role in stabilizing the intermediates and transition states involved in the ligand substitution reactions of and '. Natural population analysis (NPA) was done to determine the charge distributions on important atoms during the hydrolysis and ligand substitution reactions.

Citing Articles

[Au(N^N)Br](PF): A Class of Antibacterial and Antibiofilm Complexes (N^N = 2,2'-Bipyridine and 1,10-Phenanthroline Derivatives).

Aragoni M, Podda E, Caria V, Carta S, Cherchi M, Lippolis V Inorg Chem. 2023; 62(6):2924-2933.

PMID: 36728360 PMC: 9930124. DOI: 10.1021/acs.inorgchem.2c04410.

References

Buckley R, Elsome A, Fricker S, Henderson G, Theobald B, Parish R . Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes. J Med Chem. 1996; 39(26):5208-14. DOI: 10.1021/jm9601563. View

Ott I, Gust R . Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim). 2007; 340(3):117-26. DOI: 10.1002/ardp.200600151. View

Lau J, Ensing B . Hydrolysis of cisplatin--a first-principles metadynamics study. Phys Chem Chem Phys. 2010; 12(35):10348-55. DOI: 10.1039/b918301a. View

Perez R . Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1999; 34(10):1535-42. DOI: 10.1016/s0959-8049(98)00227-5. View

Roder C, Thomson M . Auranofin: repurposing an old drug for a golden new age. Drugs R D. 2015; 15(1):13-20. PMC: 4359176. DOI: 10.1007/s40268-015-0083-y. View

Mohamed M, Sloane B . Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006; 6(10):764-75. DOI: 10.1038/nrc1949. View

Berners-Price S, Filipovska A . Gold compounds as therapeutic agents for human diseases. Metallomics. 2011; 3(9):863-73. DOI: 10.1039/c1mt00062d. View

Nguyen P, Awwad R, Smart D, Spitz D, Gius D . Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 2005; 236(2):164-74. DOI: 10.1016/j.canlet.2005.04.028. View

Parish R, Howe B, Wright J, Mack J, Pritchard R, Buckley R . Chemical and Biological Studies of Dichloro(2-((dimethylamino)methyl)phenyl)gold(III). Inorg Chem. 1996; 35(6):1659-1666. DOI: 10.1021/ic950343b. View

10.

Zou T, Lum C, Lok C, Zhang J, Che C . Chemical biology of anticancer gold(III) and gold(I) complexes. Chem Soc Rev. 2015; 44(24):8786-801. DOI: 10.1039/c5cs00132c. View

11.

Calamai P, Carotti S, Guerri A, Mazzei T, Messori L, Mini E . Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin. Anticancer Drug Des. 1998; 13(1):67-80. View

12.

Rosenberg B, VANCAMP L, Trosko J, Mansour V . Platinum compounds: a new class of potent antitumour agents. Nature. 1969; 222(5191):385-6. DOI: 10.1038/222385a0. View

13.

Cattaruzza L, Fregona D, Mongiat M, Ronconi L, Fassina A, Colombatti A . Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts. Int J Cancer. 2010; 128(1):206-15. DOI: 10.1002/ijc.25311. View

14.

Perdew , Burke , Wang . Generalized gradient approximation for the exchange-correlation hole of a many-electron system. Phys Rev B Condens Matter. 1996; 54(23):16533-16539. DOI: 10.1103/physrevb.54.16533. View

15.

Ronconi L, Marzano C, Zanello P, Corsini M, Miolo G, Macca C . Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties. J Med Chem. 2006; 49(5):1648-57. DOI: 10.1021/jm0509288. View

16.

Pearson R . Absolute electronegativity and hardness correlated with molecular orbital theory. Proc Natl Acad Sci U S A. 1986; 83(22):8440-1. PMC: 386945. DOI: 10.1073/pnas.83.22.8440. View

17.

Anthony E, Bolitho E, Bridgewater H, Carter O, Donnelly J, Imberti C . Metallodrugs are unique: opportunities and challenges of discovery and development. Chem Sci. 2021; 11(48):12888-12917. PMC: 8163330. DOI: 10.1039/d0sc04082g. View

18.

Urig S, Fritz-Wolf K, Reau R, Herold-Mende C, Toth K, Davioud-Charvet E . Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angew Chem Int Ed Engl. 2006; 45(12):1881-6. DOI: 10.1002/anie.200502756. View

19.

Saggioro D, Rigobello M, Paloschi L, Folda A, Moggach S, Parsons S . Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem Biol. 2007; 14(10):1128-39. DOI: 10.1016/j.chembiol.2007.08.016. View

20.

Rigobello M, Messori L, Marcon G, Cinellu M, Bragadin M, Folda A . Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. J Inorg Biochem. 2004; 98(10):1634-41. DOI: 10.1016/j.jinorgbio.2004.04.020. View